» Articles » PMID: 37762745

Aortic Valve Stenosis and Cancer: Problems of Management

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Sep 28
PMID 37762745
Authors
Affiliations
Soon will be listed here.
Abstract

Aortic valve stenosis and malignancy frequently coexist and share the same risk factors as atherosclerotic disease. Data reporting the prognosis of patients with severe aortic stenosis and cancer are limited. Tailoring the correct and optimal care for cancer patients with severe aortic stenosis is complex. Cancer patients may be further disadvantaged by aortic stenosis if it interferes with their treatment by increasing the risk associated with oncologic surgery and compounding the risks associated with cardiotoxicity and heart failure (HF). Surgical valve replacement, transcatheter valve implantation, balloon valvuloplasty, and medical therapy are possible treatments for aortic valve stenosis, but when malignancy is present, the choice between these options must take into account the stage of cancer and associated treatment, expected outcome, and comorbidities. Physical examination and Doppler echocardiography are critical in the diagnosis and evaluation of aortic stenosis. The current review considers the available data on the association between aortic stenosis and cancer and the therapeutic options.

Citing Articles

Transcatheter aortic valve replacement before to breast cancer management: case report and literature review.

Aquino-Bruno H, Muratalla-Gonzalez R, Garcia-Garcia J, Morales-Portano J, Melendez-Ramirez G, Ahu-Chandomi Y Eur Heart J Case Rep. 2024; 8(9):ytae475.

PMID: 39290523 PMC: 11407282. DOI: 10.1093/ehjcr/ytae475.


Outcomes of patients with active cancer after transcatheter aortic valve replacement: an updated meta-analysis.

Felix N, Nogueira A, Carvalho P, Costa T, Tramujas L, Generoso G Cardiooncology. 2024; 10(1):55.

PMID: 39252142 PMC: 11386488. DOI: 10.1186/s40959-024-00256-8.


Multiplex, high-throughput method to study cancer and immune cell mechanotransduction.

Fabiano A, Robbins S, Knoblauch S, Rowland S, Dombroski J, King M Commun Biol. 2024; 7(1):674.

PMID: 38824207 PMC: 11144229. DOI: 10.1038/s42003-024-06327-x.

References
1.
Mack M, Brennan J, Brindis R, Carroll J, Edwards F, Grover F . Outcomes following transcatheter aortic valve replacement in the United States. JAMA. 2013; 310(19):2069-77. DOI: 10.1001/jama.2013.282043. View

2.
Belzile-Dugas E, Michel C, Morin J, Eisenberg M . The Heart-Team Approach for the Treatment of Radiation-Induced Aortic Stenosis and Coronary Artery Disease: A Case Report. CJC Open. 2021; 3(11):1388-1391. PMC: 8640575. DOI: 10.1016/j.cjco.2021.06.009. View

3.
Donnellan E, Masri A, Johnston D, Pettersson G, Rodriguez L, Popovic Z . Long-Term Outcomes of Patients With Mediastinal Radiation-Associated Severe Aortic Stenosis and Subsequent Surgical Aortic Valve Replacement: A Matched Cohort Study. J Am Heart Assoc. 2017; 6(5). PMC: 5524090. DOI: 10.1161/JAHA.116.005396. View

4.
Khrais A, Gilani N, Sapin J, Abboud Y, Kahlam A, Le A . Differential Rates of Lower Gastrointestinal Bleeding and Other Outcomes in Colorectal Cancer Patients With Aortic Stenosis. Cureus. 2023; 15(3):e35926. PMC: 10082553. DOI: 10.7759/cureus.35926. View

5.
Ezaz G, Long J, Gross C, Chen J . Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014; 3(1):e000472. PMC: 3959671. DOI: 10.1161/JAHA.113.000472. View